Drug:
Reaction: EXPOSURE VIA SKIN CONTACT
20260101 - 20261231
No. 101 - 200
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 101 | 26540951 |
US |
23 | 2 |
Eczema, Dry skin, Incorrect dose administered by product, Condition aggravated, Accidental exposure to product, Exposure via skin contact, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 102 | 26541010 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 103 | 26541028 |
US |
30 | 2 |
Device leakage, Device material issue, Drug dose omission by device, Accidental exposure to product, Exposure via skin contact, |
||||
SOMATROPIN, SOMATROPIN, |
||||
| 104 | 26541046 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 105 | 26532979 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 106 | 26532981 |
US |
54 | 1 |
Blister, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 107 | 26533379 |
US |
15 | 1 |
Injection site swelling, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 108 | 26534186 |
US |
74 | 2 |
Incorrect dose administered, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 109 | 26534398 |
US |
62 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 110 | 26534443 |
US |
76 | 1 |
Injection site haemorrhage, Accidental exposure to product, Exposure via skin contact, |
||||
SARILUMAB, |
||||
| 111 | 26534822 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 112 | 26534837 |
US |
86 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, FERROUS SULFATE, ARIPIPRAZOLE, ARIPIPRAZOLE, BRIVARACETAM, ESCITALOPRAM OXALATE, ESCITALOPRAM, PRIMIDONE, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, METHYLPHENIDATE HYDROCHLORIDE, SENNOSIDES, SENNA LEAF, SENNA, AZITHROMYCIN, AZITHROMYCIN MONOHYDRATE, AZITHROMYCIN DIHYDRATE, CALCIUM, OLMESARTAN MEDOXOMIL, METOPROLOL TARTRATE, METOROPROLOL TARTRATE, METOPROLOL, MONTELUKAST SODIUM, MONTELUKAST, ERGOCALCIFEROL, PRAMOXINE HYDROCHLORIDE, COLLOIDAL OATMEAL, PRAMOXINE HYDROCHLORIDE, MENTHOL, FOLIC ACID, DULOXETINE HYDROCHLORIDE, OLMESARTAN MEDOXOMIL, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, HYDROCHLOROTHIAZIDE, |
||||
| 113 | 26527609 |
US |
85 | 2 |
Exposure via skin contact, Wrong technique in device usage process, Wrong technique in product usage process, Accidental exposure to product, Product dose omission issue, |
||||
ALBUTEROL SULFATE, ALBUTEROL SULFATE, |
||||
| 114 | 26529332 |
US |
58 | 2 |
Exposure via skin contact, Accidental exposure to product, Product dose omission issue, Product complaint, |
||||
BELIMUMAB, |
||||
| 115 | 26531081 |
US |
2 | |
Skin discolouration, Exposure via skin contact, Accidental exposure to product, Product quality issue, |
||||
| 116 | 26522655 |
US |
39 | 2 |
Exposure via skin contact, Accidental exposure to product, Product complaint, |
||||
BELIMUMAB, |
||||
| 117 | 26522891 |
US |
69 | 2 |
Exposure via skin contact, Wrong technique in device usage process, Product dose omission issue, Accidental exposure to product, Underdose, Product use in unapproved indication, Product complaint, |
||||
MEPOLIZUMAB, |
||||
| 118 | 26524532 |
US |
68 | 2 |
Device delivery system issue, Accidental exposure to product, Exposure via skin contact, |
||||
ABATACEPT, |
||||
| 119 | 26525288 |
US |
2 | |
Device defective, Exposure via skin contact, No adverse event, |
||||
OMALIZUMAB, |
||||
| 120 | 26526233 |
US |
72 | 1 |
Exposure via skin contact, Device use error, Product dose omission issue, Accidental exposure to product, |
||||
MEPOLIZUMAB, MEPOLIZUMAB, |
||||
| 121 | 26521969 |
US |
24 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 122 | 26522110 |
US |
36 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 123 | 26522116 |
US |
34 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 124 | 26522120 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 125 | 26522181 |
US |
2 | |
Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 126 | 26522205 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 127 | 26522212 |
US |
10 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 128 | 26522224 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 129 | 26522236 |
US |
78 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 130 | 26522254 |
US |
24 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 131 | 26522276 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 132 | 26522282 |
US |
68 | 1 |
Productive cough, Viral infection, Diarrhoea, Vomiting, Dehydration, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, GLIPIZIDE, GLIPIZIDE-TABLETS, INSULIN LISPRO, EMPAGLIFLOZIN, LINACLOTIDE, LOSARTAN POTASSIUM, LOSARTAN, METFORMIN HYDROCHLORIDE, METFORMIN, METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS, METFORMIN HYDROCHLORIDE TABLET, METFORMIN HYDROCHLORIDE TABLETS, TIRZEPATIDE, ROSUVASTATIN, TADALAFIL, |
||||
| 133 | 26522305 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 134 | 26521363 |
US |
2 | |
Injection site haemorrhage, Injection site discomfort, Injury associated with device, Needle issue, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 135 | 26521382 |
US |
48 | 2 |
Alopecia, Injection site extravasation, Eczema, Skin lesion, Skin exfoliation, Pruritus, Skin hypopigmentation, Dry skin, Skin hypertrophy, Dermatitis atopic, Rash pruritic, Skin discolouration, Rash, Injection site vesicles, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 136 | 26521401 |
US |
74 | 1 |
Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, TIRZEPATIDE, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, |
||||
| 137 | 26521407 |
US |
27 | 2 |
Accidental exposure to product, Exposure via skin contact, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, |
||||
| 138 | 26521564 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 139 | 26521567 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 140 | 26521616 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 141 | 26521617 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 142 | 26521619 |
US |
66 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 143 | 26521621 |
US |
30 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 144 | 26521643 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 145 | 26521655 |
US |
69 | 2 |
Off label use, Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 146 | 26521663 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 147 | 26521666 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 148 | 26521755 |
US |
||
Exposure via skin contact, Accidental exposure to product, |
||||
DUPILUMAB, |
||||
| 149 | 26521765 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 150 | 26521775 |
US |
32 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 151 | 26521788 |
US |
47 | 1 |
Injection site vesicles, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 152 | 26521822 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 153 | 26521883 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 154 | 26521895 |
US |
68 | 2 |
Injection site pain, Injection site swelling, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 155 | 26521940 |
US |
39 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 156 | 26521950 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 157 | 26516990 |
US |
59 | 2 |
Exposure via skin contact, Product storage error, Accidental exposure to product, Product complaint, |
||||
BELIMUMAB, |
||||
| 158 | 26517903 |
US |
44 | 2 |
Exposure via skin contact, Device issue, No adverse event, |
||||
OMALIZUMAB, |
||||
| 159 | 26517973 |
US |
47 | 2 |
Product dose omission issue, Exposure via skin contact, Product storage error, Needle issue, No adverse event, |
||||
OMALIZUMAB, |
||||
| 160 | 26518703 |
US |
48 | 2 |
Exposure via skin contact, Accidental exposure to product, Wrong technique in device usage process, Incorrect dose administered, Product complaint, |
||||
BELIMUMAB, |
||||
| 161 | 26519396 |
US |
38 | 2 |
Device delivery system issue, Exposure via skin contact, Product knowledge deficit, Accidental exposure to product, |
||||
ABATACEPT, |
||||
| 162 | 26512292 |
US |
72 | 2 |
Device delivery system issue, Incorrect dose administered by device, Exposure via skin contact, |
||||
ABATACEPT, |
||||
| 163 | 26508541 |
US |
2 | |
Accidental exposure to product, Occupational exposure to product, Exposure via skin contact, |
||||
EVOLOCUMAB, |
||||
| 164 | 26509223 |
US |
71 | 2 |
Drug ineffective, Product use issue, Accidental exposure to product, Exposure via skin contact, Product delivery mechanism issue, |
||||
EFINACONAZOLE, EFINACONAZOLE, |
||||
| 165 | 26510417 |
US |
52 | 2 |
Device delivery system issue, Accidental exposure to product, Exposure via skin contact, Incorrect dose administered, |
||||
ABATACEPT, |
||||
| 166 | 26510484 |
US |
60 | 2 |
Device delivery system issue, Accidental exposure to product, Exposure via skin contact, Needle issue, |
||||
ABATACEPT, |
||||
| 167 | 26511757 |
US |
17 | 1 |
Accidental exposure to product, Exposure via skin contact, Device leakage, |
||||
SOMATROPIN, SOMATROPIN, |
||||
| 168 | 26503046 |
US |
53 | 2 |
Device difficult to use, Accidental exposure to product, Exposure via skin contact, |
||||
ERENUMAB-AOOE, |
||||
| 169 | 26503566 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
EVOLOCUMAB, |
||||
| 170 | 26507296 |
US |
70 | 1 |
Incorrect dose administered by device, Accidental exposure to product, Exposure via skin contact, Device difficult to use, |
||||
EVOLOCUMAB, EVOLOCUMAB, |
||||
| 171 | 26497913 |
US |
79 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
EVOLOCUMAB, EVOLOCUMAB, |
||||
| 172 | 26497977 |
US |
75 | 2 |
Accidental exposure to product, Device difficult to use, Exposure via skin contact, |
||||
EVOLOCUMAB, |
||||
| 173 | 26498412 |
US |
53 | |
Exposure via skin contact, Accidental exposure to product, |
||||
EVOLOCUMAB, |
||||
| 174 | 26499143 |
US |
2 | |
Device difficult to use, Accidental exposure to product, Exposure via skin contact, Device use error, |
||||
ETANERCEPT, |
||||
| 175 | 26499978 |
US |
38 | 2 |
Accidental exposure to product, Exposure via skin contact, Device difficult to use, |
||||
ERENUMAB-AOOE, |
||||
| 176 | 26500185 |
US |
2 | |
Exposure via skin contact, Incorrect dose administered by device, Wrong technique in device usage process, Accidental exposure to product, Overdose, |
||||
MEPOLIZUMAB, |
||||
| 177 | 26500463 |
US |
68 | 2 |
Hip arthroplasty, Exposure via skin contact, Accidental exposure to product, Incorrect dose administered by device, Device difficult to use, |
||||
EVOLOCUMAB, |
||||
| 178 | 26500691 |
US |
28 | 2 |
Oesophageal food impaction, Dysphagia, Odynophagia, Retching, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 179 | 26502590 |
US |
70 | 2 |
Device delivery system issue, Device failure, Product knowledge deficit, Exposure via skin contact, |
||||
ABATACEPT, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, BACLOFEN, DULOXETINE HYDROCHLORIDE, FAMOTIDINE, FLUTICASONE PROPIONATE, ACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, PHENYLEPHRINE HCL, ALENDRONATE SODIUM, LOSARTAN, ESOMEPRAZOLE MAGNESIUM, MONTELUKAST SODIUM, TIOTROPIUM BROMIDE, ERGOCALCIFEROL, DICLOFENAC SODIUM, |
||||
| 180 | 26497616 |
US |
64 | 2 |
Injection site bruising, Injection site haematoma, Accidental exposure to product, Exposure via skin contact, Product administration error, Wrong technique in product usage process, |
||||
EVOLOCUMAB, |
||||
| 181 | 26497622 |
US |
59 | 1 |
Device difficult to use, Drug dose omission by device, Accidental exposure to product, Exposure via skin contact, |
||||
ETANERCEPT, |
||||
| 182 | 26497678 |
US |
1 | |
Glycosylated haemoglobin decreased, Exposure via skin contact, Accidental exposure to product, |
||||
INSULIN GLARGINE, INSULIN GLARGINE, |
||||
| 183 | 26497734 |
US |
79 | 1 |
Accidental exposure to product, Exposure via skin contact, Product communication issue, Device use error, |
||||
EVOLOCUMAB, |
||||
| 184 | 26497011 |
US |
50 | 1 |
Wrong technique in product usage process, Exposure via skin contact, Accidental exposure to product, |
||||
EVOLOCUMAB, |
||||
| 185 | 26497055 |
US |
70 | 2 |
Exposure via skin contact, Accidental exposure to product, Wrong technique in device usage process, |
||||
MEPOLIZUMAB, |
||||
| 186 | 26497072 |
US |
74 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
EVOLOCUMAB, |
||||
| 187 | 26497231 |
US |
70 | 2 |
Illness, Brain neoplasm malignant, Exposure via skin contact, Injection site pain, Accidental exposure to product, Incorrect dose administered, Off label use, Product complaint, |
||||
MEPOLIZUMAB, |
||||
| 188 | 26492262 |
US |
77 | 1 |
Accidental exposure to product, Exposure via skin contact, Device difficult to use, Drug dose omission by device, |
||||
EVOLOCUMAB, |
||||
| 189 | 26493292 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 190 | 26493406 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 191 | 26494613 |
AU |
1 | |
Device leakage, Device deployment issue, Exposure via skin contact, Incorrect dose administered, |
||||
GOLIMUMAB, |
||||
| 192 | 26495929 |
US |
68 | 2 |
Dizziness, Pain, Arthralgia, Hypoaesthesia, Pruritus, Product administration error, Exposure via skin contact, Underdose, |
||||
SIBEPRENLIMAB, SIBEPRENLIMAB, |
||||
| 193 | 26496099 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 194 | 26485538 |
US |
73 | 2 |
Device delivery system issue, Accidental exposure to product, Exposure via skin contact, |
||||
ABATACEPT, |
||||
| 195 | 26486460 |
US |
57 | 2 |
Pneumonia, Urticaria, Scratch, Influenza, Asthma, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 196 | 26488219 |
US |
68 | 2 |
Injection site haemorrhage, Injection site swelling, Exposure via skin contact, Product delivery mechanism issue, |
||||
ALIROCUMAB, |
||||
| 197 | 26488509 |
US |
73 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 198 | 26489581 |
US |
70 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE-YFGN, INSULIN GLARGINE, |
||||
| 199 | 26489664 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 200 | 26489771 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-04-28